ArticleBreast cancer research : BCR2014
TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients.
Article in Breast cancer research : BCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 105 citations in OpenAlex.
- Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells.Exploration (Beijing, China) · 2026Review
- Phenotypic Characterization and Sorting of Circulating Tumor Cells (CTCs) Using a Digital Image-Based Sorter.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Prediction of Lung Cancer Metastasis Risk Based on Single-Cell Metabolic Profiling of Circulating Tumor Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Association of androgen receptor and tumour-infiltrating lymphocytes with bone recurrence in triple-negative breast cancer.Journal of bone oncology · 2024Article
- Phosphorylation of USP27X by GSK3β maintains the stability and oncogenic functions of CBX2.Cell death & disease · 2023Article
- Review
- Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?International journal of molecular sciences · 2022Review
- Article
- Detection of circulating tumor cells: opportunities and challenges.Biomarker research · 2022Review
- Review
- Single-Cell Sequencing and Its Applications in Liver Cancer.Frontiers in oncology · 2022Review
- Circulating tumor cells: biology and clinical significance.Signal transduction and targeted therapy · 2021Review
- Using single-cell sequencing technology to detect circulating tumor cells in solid tumors.Molecular cancer · 2021Review
- The Polemic Diagnostic Role ofCancers · 2020Review
- Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling.International journal of molecular sciences · 2020Article
- Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds.International journal of molecular sciences · 2020Review
- The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor.Molecular therapy oncolytics · 2019Article
- Review
- CTC analysis: an update on technological progress.Translational research : the journal of laboratory and clinical medicine · 2019Review
- CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs).Cells · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
introductionCirculating tumor cells (CTCs) are tumor cells shed from either primary tumors or its metastases that circulate in the peripheral blood of patients with metastatic cancers. The molecular characterization of the CTCs is critical to identifying the key drivers of cancer metastasis and devising therapeutic approaches. However, the molecular characterization of CTCs is difficult to achieve because their isolation is a major technological challenge.
methodsCTCs from two triple negative breast cancer patients were enriched using CellSearch and single cells selected by DEPArray™. A TP53 R110 fs*13 mutation identified by next generation sequencing in the breast and chest skin biopsies of both patients was studied in single CTCs.
resultsFrom 6 single CTC isolated from one patient, 1 CTC had TP53 R110 delC, 1 CTC showed the TP53 R110 delG mutation, and the remaining 4 single CTCs showed the wild type p53 sequence; a pool of 14 CTCs isolated from the same patient also showed TP53 R110 delC mutation. In the tumor breast tissue of this patient, only the TP53 R110 delG mutation was detected. In the second patient a TP53 R110 delC mutation was detected in the chest wall skin biopsy; from the peripheral blood of this patient, 5 single CTC and 6 clusters of 2 to 6 CTCs were isolated; 3 of the 5 single CTCs showed the TP53 R110 delC mutation and 2 CTCs showed the wild type TP53 allele; from the clusters, 5 showed the TP53 R110 delC mutation, and 1 cluster the wild type TP53 allele. Single white blood cells isolated as controls from both patients only showed the wild type TP53 allele.
conclusionsWe are able to isolate uncontaminated CTCs and achieve single cell molecular analysis. Our studies showed the presence of different CTC sub-clones in patients with metastatic breast cancer. Some CTCs had the same TP53 mutation as their matching tumor samples although others showed either a different TP53 mutation or the wild type allele. Our results indicate that CTCs could represent a non-invasive source of cancer cells from which to determine genetic markers of the disease progression and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.